Last $1.67 USD
Change Today -0.0099 / -0.59%
Volume 468.5K
ZGNX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 11:35 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

zogenix inc (ZGNX) Snapshot

Open
$1.67
Previous Close
$1.68
Day High
$1.69
Day Low
$1.65
52 Week High
03/5/14 - $4.68
52 Week Low
10/13/14 - $1.07
Market Cap
256.3M
Average Volume 10 Days
3.1M
EPS TTM
$-0.63
Shares Outstanding
153.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZOGENIX INC (ZGNX)

zogenix inc (ZGNX) Details

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders and pain. The company’s commercial product includes Zohydro, a single-entity extended-release hydrocodone for the treatment of moderate to severe chronic pain. It also develops Relday, an injectable formulation of risperidone, which is in a Phase I clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.

114 Employees
Last Reported Date: 03/7/14
Founded in 2006

zogenix inc (ZGNX) Top Compensated Officers

Chief Executive Officer, Interim Chief Commer...
Total Annual Compensation: $449.3K
President and Director
Total Annual Compensation: $370.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $335.1K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $71.5K
Compensation as of Fiscal Year 2013.

zogenix inc (ZGNX) Key Developments

Zogenix, Inc. Appoints Renee Tannenbaum, Pharm.D. to its Board of Directors

Zogenix, Inc. announced that Renee Tannenbaum, Pharm.D., has been appointed as a new member of the company's board of directors. Dr. Tannenbaum currently serves as the Head of Global Customer Excellence of AbbVie, Inc., where she is responsible for building commercial capabilities for the organization. Prior to joining the industry, Dr. Tannenbaum was an Assistant Professor of Clinical Pharmacy at the Philadelphia College of Pharmacy and Sciences, now known as the University of the Sciences at Philadelphia. She retains a faculty position at the University's Mayes College of Healthcare Business and Policy and serves as the Dean's Professor.

Zogenix Inc. Receives Approval for New Version of Painkiller

Zogenix Inc. has received U.S. approval for a new formulation of its much-debated painkiller Zohydro that is intended to be harder to abuse, though the company is still working on studies needed to promote that claim. The Food and Drug Administration late Friday approved new Zohydro Extended Release capsules which are designed to form a thick gel when crushed or dissolved in liquid. People who abuse prescription painkillers typically crush or dissolve them for snorting or injecting. The company announced that it will replace the currently available version of the drug with the new formulation during the second quarter of the year. Despite the new design, Zohydro's label will not yet carry any claims that the drug is more difficult to abuse. The FDA requires drugmakers to submit clinical data demonstrating abuse-deterrent properties before promoting them to doctors or patients.

Zogenix, Inc. Receives FDA Approval of New Formulation of Zohydro(R) ER

Zogenix, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a new formulation of Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with BeadTek⠢. BeadTek is a formulation technology designed to provide abuse-deterrent properties without changing the release properties of hydrocodone when Zohydro ER is used as intended. Concurrently, Zogenix has ongoing Human Abuse Liability studies, which will further characterize the abuse-deterrent properties of the new formulation. Zogenix intends to submit these data in the second half of 2015 to the FDA to support an amended product label, including abuse-deterrent claims consistent with the FDA's current draft Guidance for Industry, Abuse-Deterrent Opioids ⠓ Evaluation and Labeling. BeadTek incorporates well-known pharmaceutical excipients that immediately form a viscous gel when crushed and dissolved in liquids or solvents. Zohydro ER is the only long-acting hydrocodone product administered every 12 hours, and the new formulation maintains the same efficacy and pharmacokinetic profile of the original formulation. Transition to Zohydro ER with BeadTek is expected to occur in the second quarter of 2015 for all prescribed strengths ranging from 10 mg to 50 mg, without disruption to patients currently on therapy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZGNX:US $1.67 USD -0.0099

ZGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Corium International Inc $6.97 USD 0.00
Eternity Healthcare Inc $0.05 USD +0.012
View Industry Companies
 

Industry Analysis

ZGNX

Industry Average

Valuation ZGNX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.6x
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOGENIX INC, please visit www.zogenix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.